952566-04-0

Basic information

• Product Name: IMidazo[1,2-a]pyridine-7-...
• Synonyms: Imidazo[1,2-a]pyridine-7-carbonitrile
• CAS NO: 952566-04-0
• Molecular Formula: C8H5N3
• Molecular Weight: 143.1454
• Mol File: 952566-04-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: IMidazo[1,2-a]pyridine-7-...(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine-7-...(952566-04-0)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine-7-...(952566-04-0)

Safety Data

• Hazardous Substances Data: 952566-04-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
IDP-328 is used as a potential therapeutic agent for the treatment of various conditions, primarily due to its ability to inhibit the activity of enzymes and proteins involved in these diseases. Its application is particularly focused on conditions such as cancer and autoimmune diseases, where its inhibitory effects on specific biological targets could lead to novel treatment options.
Used in Cancer Treatment:
In the field of oncology, IDP-328 is used as a potential anticancer agent. It is being studied for its capacity to target and inhibit enzymes and proteins that play a role in the development and progression of cancer. IMidazo[1,2-a]pyridine-7-...'s mechanism of action could provide a new avenue for cancer treatment, offering an alternative or complementary approach to existing therapies.
Used in Autoimmune Disease Management:
IDP-328 is also being explored for its potential in managing autoimmune diseases. Its ability to modulate the activity of proteins involved in the immune response suggests that it could be utilized to treat conditions where the immune system mistakenly attacks the body's own tissues. This application could lead to new treatment strategies for a range of autoimmune disorders.

Upstream product

• 107-20-0 2-chloroethanal 
• 42182-27-4 4-cyanopyridin-2-amine 
• 557-21-1 zinc(II) cyanide 
• 4532-25-6 7-chloroimidazo-[1,2-a]pyridine 

Relevant articles and documents

SALT INDUCIBLE KINASE INHIBITORS

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.

Preparation method of aromatic nitrile compound or heteroaromatic nitrile compound

The invention discloses a preparation method of an aromatic nitrile compound or a heteroaromatic nitrile compound. The preparation method comprises: under the protection of an inert gas, in a solvent,under the actions of a nickel catalyst, a ligand, metal zinc and an additive, carrying out a reaction on a cyanation reagent and halogenated aromatic hydrocarbon or halogenated heteroaromatic hydrocarbon. According to the present invention, by using the inexpensive and easily-available nickel catalyst and the ligand, the halogenated aromatic hydrocarbon or halogenated heteroaromatic hydrocarbon,especially the chlorinated aromatic hydrocarbon or chlorinated heteroaromatic hydrocarbon with characteristics of low price, easy obtaining and low reaction activity can mildly and efficiently react with the cyanation reagent with low toxicity to prepare the aromatic nitrile compound or heteroaromatic nitrile compound; and the preparation method has advantages of simple operation, mildness, high efficiency and the like, and further has characteristics of good functional group compatibility, good universality of substrate and the like.

General and Mild Nickel-Catalyzed Cyanation of Aryl/Heteroaryl Chlorides with Zn(CN)2: Key Roles of DMAP

A new and general nickel-catalyzed cyanation of hetero(aryl) chlorides using less toxic Zn(CN)2 as the cyanide source has been developed. The reaction relies on the use of inexpensive NiCl2·6H2O/dppf/Zn as the catalytic system and DMAP as the additive, allowing the cyanation to occur under mild reaction conditions (50-80 °C) with wide functional group tolerance. DMAP was found to be crucial for successful transformation, and the reaction likely proceeds via a Ni(0)/Ni(II) catalysis based on mechanistic studies. The method was also successfully extended to aryl bromides and aryl iodides.

NEW COMPOUNDS

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.